Deutsche Bank Aktiengesellschaft Begins Coverage on MMED (NASDAQ:MMED)

Analysts at Deutsche Bank Aktiengesellschaft initiated coverage on shares of MMED (NASDAQ:MMED) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 39.37% from the stock’s previous close.

MMED has been the topic of several other reports. BTIG Research assumed coverage on shares of MMED in a research report on Tuesday. They issued a “buy” rating and a $25.00 price target on the stock. Wells Fargo & Company started coverage on MMED in a research report on Tuesday. They set an “overweight” rating and a $26.00 target price on the stock. Piper Sandler assumed coverage on MMED in a research note on Tuesday. They issued a “neutral” rating and a $16.00 price objective on the stock. The Goldman Sachs Group initiated coverage on MMED in a research note on Tuesday. They set a “buy” rating and a $24.00 price objective for the company. Finally, Evercore began coverage on shares of MMED in a report on Tuesday. They set an “outperform” rating and a $20.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.10.

MMED Stock Down 0.8%

MMED stock opened at $14.35 on Tuesday. MMED has a 1 year low of $14.10 and a 1 year high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.